Cormorant Asset Management, LP — 13F Holdings & Portfolio
CIK 1583977 · latest 13F-HR filed 2026-05-15
Cormorant Asset Management, LP manages $1.99B in 13F-reported U.S. long-equity assets across 47 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are PRAX (14.33%), BBOT (8.04%), EYPT (5.35%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 17 new positions, exited 3, added to 9, and trimmed 14.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$1.99B
Long-equity book
47
Distinct positions
2026-03-31
Filed 2026-05-15
+17 / −3 / ↑9 / ↓14
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ALUMIS INC$51.5M +145.2%
- MOONLAKE IMMUNOTHERAPEUTICS$26.1M +45.5%
- BIOAGE LABS INC$23.6M +87.3%
- EDGEWISE THERAPEUTICS INC$21.2M +26.0%
- BIOHAVEN LTD$14.8M +13088.3%
Top Trims
- ABIVAX SA-$97.4M -53.5%
- BRIDGEBIO ONCOLOGY THERAPEUT-$63.8M -28.5%
- EYEPOINT INC-$44.5M -29.4%
- BRIDGEBIO PHARMA INC-$28.7M -31.2%
- INSMED INC-$16.8M -35.1%
New Positions
- ERASCA INC$93.8M
- DIANTHUS THERAPEUTICS INC$79.7M
- DAMORA THERAPEUTICS INC$39.5M
- TANGO THERAPEUTICS INC$29.8M
- AGOMAB THERAPEUTICS NV$25.9M
Exited Positions
- ENGENE HOLDINGS INC$36.1M
- GH RESEARCH PLC$16.5M
- JANUX THERAPEUTICS INC$9.0M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $285.3M | 14.33% | 885,500 | SH |
| 2 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $160.0M | 8.04% | 17,878,594 | SH |
| 3 | EYEPOINT INC | EYPT | 30233G209 | $106.5M | 5.35% | 8,265,000 | SH |
| 4 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $102.7M | 5.16% | 3,260,000 | SH |
| 5 | ERASCA INC | ERAS | 29479A108 | $93.8M | 4.71% | 5,800,000 | SH |
| 6 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $92.5M | 4.65% | 2,957,521 | SH |
| 7 | ALUMIS INC | ALMS | 022307102 | $87.0M | 4.37% | 3,949,241 | SH |
| 8 | ABIVAX SA | ABVX | 00370M103 | $84.6M | 4.25% | 760,000 | SH |
| 9 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $83.5M | 4.19% | 4,480,433 | SH |
| 10 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $79.7M | 4.00% | 950,000 | SH |
| 11 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $77.3M | 3.88% | 1,059,331 | SH |
| 12 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $63.1M | 3.17% | 850,000 | SH |
| 13 | OLEMA PHARMACEUTICALS INC | OLMA | 68062P106 | $58.1M | 2.92% | 3,900,000 | SH |
| 14 | BIOAGE LABS INC | BIOA | 09077V100 | $50.6M | 2.54% | 2,890,605 | SH |
| 15 | CENTESSA PHARMACEUTICALS PLC | CNTA | 152309100 | $41.7M | 2.09% | 1,050,000 | SH |
| 16 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $39.5M | 1.98% | 1,525,000 | SH |
| 17 | MBX BIOSCIENCES INC | MBX | 55287L101 | $33.4M | 1.68% | 1,120,000 | SH |
| 18 | INSMED INC | INSM | 457669307 | $31.1M | 1.56% | 190,000 | SH |
| 19 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $30.4M | 1.53% | 950,000 | SH |
| 20 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $29.8M | 1.50% | 1,425,000 | SH |
| 21 | PHARVARIS N V | PHVS | N69605108 | $28.2M | 1.42% | 1,000,000 | SH |
| 22 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $26.2M | 1.31% | 533,340 | SH |
| 23 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $25.9M | 1.30% | 2,465,348 | SH |
| 24 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $22.4M | 1.12% | 750,000 | SH |
| 25 | CORBUS PHARMACEUTICALS HLDGS | CRBP | 21833P301 | $22.0M | 1.11% | 2,344,971 | SH |
| 26 | ASCENDIS PHARMA A/S | ASND | 04351P101 | $21.7M | 1.09% | 95,000 | SH |
| 27 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $20.8M | 1.04% | 750,000 | SH |
| 28 | ADLAI NORTYE LTD | ANL | 00704R109 | $20.1M | 1.01% | 2,897,857 | SH |
| 29 | TERNS PHARMACEUTICALS INC | TERN | 880881107 | $15.8M | 0.79% | 300,000 | SH |
| 30 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $15.8M | 0.79% | 225,000 | SH |
| 31 | BIOHAVEN LTD | BHVN | G1110E107 | $14.9M | 0.75% | 1,760,000 | SH |
| 32 | CABALETTA BIO INC | CABA | 12674W109 | $14.8M | 0.74% | 5,500,000 | SH |
| 33 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $13.2M | 0.66% | 1,297,500 | SH |
| 34 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $10.6M | 0.53% | 450,000 | SH |
| 35 | SENSEI BIOTHERAPEUTICS INC | SNSE | 81728A207 | $9.7M | 0.48% | 306,222 | SH |
| 36 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $9.1M | 0.46% | 250,000 | SH |
| 37 | ZURA BIO LTD | ZURA | G9TY5A101 | $8.6M | 0.43% | 1,450,000 | SH |
| 38 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $8.5M | 0.42% | 50,000 | SH |
| 39 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $8.4M | 0.42% | 175,000 | SH |
| 40 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $7.7M | 0.39% | 200,000 | SH |
| 41 | OLEMA PHARMACEUTICALS INC Call | OLMA | 68062P106 | $7.5M | 0.37% | 500,000 | SH |
| 42 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $6.6M | 0.33% | 400,000 | SH |
| 43 | ARROWHEAD PHARMACEUTICALS IN | ARWR | 04280A100 | $6.3M | 0.31% | 100,000 | SH |
| 44 | VAXCYTE INC | PCVX | 92243G108 | $5.8M | 0.29% | 100,000 | SH |
| 45 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $4.9M | 0.24% | 350,000 | SH |
| 46 | RALLYBIO CORP | RLYB | 75120L209 | $3.6M | 0.18% | 400,000 | SH |
| 47 | CONTEXT THERAPEUTICS INC | CNTX | 21077P108 | $1.4M | 0.07% | 529,550 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $1.99B | 47 | 0001583977-26-000002 |
| 2025-12-31 | 2026-02-17 | $2.16B | 35 | 0001583977-26-000001 |
| 2025-09-30 | 2025-11-14 | $1.45B | 36 | 0001583977-25-000011 |